NICE UK approves Roche's PD-L1 single anti-Tecentriq treatment for triple-negative breast cancer after offering big discount

The National Institute of Health and Clinical Excellence (NICE) has approved its immunotherapy PD-L1 monoantiticriq (atezolizumab) for the treatment of triple-negative breast cancer (TNBC) patients after Roche offered a significant discount to the NHS in the UKAT THE END OF LAST YEAR, NICE DID NOT RECOMMEND TECENTRIQ BECAUSE THE DRUG WAS NOT COST-EFFECTIVE ON TNBC AND COULD NOT EVEN EXTEND ITS LIFEAT THE TIME, NICE ADDED THAT ROCHE'S PD-L1 MONOAB "IS NOT POTENTIALLY COST-EFFECTIVE AT CURRENT PRICES AND THERE IS NO CLEAR EVIDENCE THAT FURTHER TRIALS CAN ADDRESS THE UNCERTAINTY OF PD-L1 MONOANTINOS"Under NICE's advice, Roche offered confidential discounts to the NHSTNBC is a aggressive form of breast cancer with few other treatment options than surgery, radiotherapy and chemotherapyTNBC tumors also lack estrogen, progesterone and HER2 receptors, making it impossible to use drugs that target these biomarkersThe recommendation is based on the results of the IMpassion130 3 study, in which Tecentriq and Celgene's Abraxane (nab-yew alcohol) had a progression-free lifetime of 2.5 months and a total lifetime of approximately 9.5 monthsNICE now recommends Tecentriq, along with Abraxane, for metastatic TNBC patients who have not yet received chemotherapy treatment and are unable to operateRival Merck's PD-1 monoantibuta (pembrolizumab) did not show the same effect on TNBC